ClinicalTrials.gg
Active, not recruitingNCT07013643Updated Oct 13, 2026

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

A Phase 1 interventional study of AZD6234 and Ethinyl estradiol/Levonorgestrel (EE/LEVO) in Healthy Participants, sponsored by AstraZeneca. Active, not recruiting at 2 sites in United States. Open to female participants aged 35 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Updated Oct 13, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
35 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing AZD6234 in Obesity — 2 open to participants now, 4 under way, 1 of them phase 3. AZD6234 · Obesity.

Enrollment
5th of 10
100 · median 85
Started
2025
with 4 others
Phase 1
5 of 10
1 open now
Registered
7th of 10
by date
Lead sponsor
10 of 10
AstraZeneca

Among the 10 studies testing AZD6234 in Obesity, this one is the 5th largest by enrollment, is one of 5 that started in 2025, is one of 5 in phase 1, and was the 7th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 10 studies testing AZD6234 in Obesity are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About AZD6234

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 35 Years to 75 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing AZD6234 in Obesity, or all of them as a file.
02

Study summary

This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol (EE)/levonorgestrel (LEVO) in healthy female participants with obesity.

Read the detailed description

This is a Phase I, open-label, single-sequence, multiple-cohort study which will be performed at multiple study sites in healthy females of childbearing and non-childbearing potential.

The purpose of this study is to investigate the effect of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 on the PK, safety and tolerability of a CoC, ethinyl estradiol/levonorgestrel (EE/LEVO).

The study will have 4 cohorts, and each cohort will consist of 5 periods which include, Screening, Start, Up-titration, Maintenance, and Follow-up periods.

03

Conditions studied

  • Healthy Participants

Keywords

  • Obesity
  • Overweight
  • Oral contraceptives
  • Pharmacokinetics
  • Drug Interaction
04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All participants must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
  • Females of must not be lactating and if heterosexually active, must agree to use an approved method of highly effective .

    o Hormonal contraceptives and estrogen-containing hormonal methods of birth control are not permitted due to potential effect and influence on the results using a CoC assessment.

  • Females of non-childbearing potential must be confirmed at the Screening Visit.
  • Have a (BMI) between 25 and 40 kg/m2, both inclusive and weigh at least 60 kg for Cohorts 1, 2, and 3 and a BMI of > 30 kg/m2 for Cohort 4.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder (gastroparesis, deep vein thrombosis, venous thromboembolism, previous surgery of the upper gastrointestinal tract, cardiovascular disease, neuromuscular or neurogenic disease, severe vitamin D deficiency (cohort 1, cohort 2 and cohort 4), type I or type II diabetes mellitus, (HbA1c) ≥ 6.5% at screening, history of neoplastic disease (cohort 2, cohort 3 and cohort 4), basal calcitonin level >50 ng/L (50 pg/L) at screening (cohort 2, cohort 3 and cohort 4), history of acute or chronic pancreatitis or pancreatic amylase or lipase >2× at screening (cohort 2, cohort 3 and cohort 4), prior history of cholecystectomy or untreated cholelithiasis and personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN2) (cohort 2, cohort 3 and cohort 4).
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma.
  • Any laboratory values with deviations or clinically important abnormalities in clinical chemistry, hematology, or urinalysis.
  • Any positive result on screening for serum surface antigen (HBsAg), Hepatitis B core antibody (HBcAb) or (HIV).
  • Abnormal vital signs.
  • Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12 lead (ECG), at screening.
  • Current smokers or those who have smoked or used nicotine products.
  • Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity.
  • Statin treatment within 4 weeks prior to the start of study treatment.
  • Current use of estrogen-containing products.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Cohort-1: AZD6234 + EE/LEVO + Acetaminophen (APAP)

    All participants will receive CoC (EE/LEVO) and separately, APAP, treatments throughout the study during the up-titration and maintenance periods of subcutaneous AZD6234 administration.

    Drug: AZD6234 · Drug: Ethinyl estradiol/Levonorgestrel (EE/LEVO) · Drug: Acetaminophen (APAP)

  • Experimental
    Cohort-2: AZD6234+AZD9550+EE/LEVO+APAP

    All participants will receive CoC (EE/LEVO) and separately, APAP, treatments throughout the study during the up-titration and maintenance periods of subcutaneous AZD6234 (up to a maximum dose of Dose X1) and AZD9550 (up to a maximum dose of Dose Y1) administration.

    Drug: AZD6234 · Drug: Ethinyl estradiol/Levonorgestrel (EE/LEVO) · Drug: Acetaminophen (APAP) · Drug: AZD9550

  • Experimental
    Cohort-3: AZD9550 + EE/LEVO + APAP

    All participants will receive CoC (EE/LEVO) and separately, APAP, treatments throughout the study during the up-titration and maintenance periods of subcutaneous AZD9550 administration.

    Drug: Ethinyl estradiol/Levonorgestrel (EE/LEVO) · Drug: Acetaminophen (APAP) · Drug: AZD9550

  • Experimental
    Cohort-4: AZD6234+AZD9550+EE/LEVO+APAP

    All participants will receive CoC (EE/LEVO) and separately, APAP, treatments throughout the study during the up-titration and maintenance periods of subcutaneous AZD6234 (up to a maximum dose of Dose X2) and AZD9550 (up to a maximum dose of Dose Y1) administration.

    Drug: AZD6234 · Drug: Ethinyl estradiol/Levonorgestrel (EE/LEVO) · Drug: Acetaminophen (APAP) · Drug: AZD9550

Interventions

  • AZD6234 will be administered as a subcutaneous injection in the abdomen.

  • DrugEthinyl estradiol/Levonorgestrel (EE/LEVO)

    EE/LEVO will be administered as combined oral tablets.

  • APAP will be administered orally as a solution.

  • AZD9550 will be administered as a subcutaneous injection in the abdomen.

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve from time 0 to infinity (AUCinf) of EE and LEVO

    To assess the effect of multiple doses of AZD6234, multiple doses of co-administered AZD9550 and AZD6234, and multiple doses of AZD9550 on the PK of single doses of CoC EE/LEVO.

    Time frame: Cohort 1: At predefined intervals from Day -5 up to Day 99; Cohort 2 : At pre-defined interval from Day -5 up to Day 169; Cohort 3: At predefined intervals from Day -5 up to Day 225; Cohort 4: At predefined intervals from Day -5 up to Day 253

  2. Area under the concentration-time curve from time of dosing to the last measurable concentration (AUClast) of EE and LEVO

    To assess the effect of multiple doses of AZD6234, multiple doses of co-administered AZD9550 and AZD6234, and multiple doses of AZD9550 on the PK of single doses of CoC EE/LEVO.

    Time frame: Cohort 1: At predefined intervals from Day -5 up to Day 99; Cohort 2 : At pre-defined interval from Day -5 up to Day 169; Cohort 3: At predefined intervals from Day -5 up to Day 225; Cohort 4: At predefined intervals from Day -5 up to Day 253

  3. Maximum plasma concentration (Cmax) of EE and LEVO

    To assess the effect of multiple doses of AZD6234, multiple doses of co-administered AZD9550 and AZD6234, and multiple doses of AZD9550 on the PK of single doses of CoC EE/LEVO.

    Time frame: Cohort 1: At predefined intervals from Day -5 up to Day 99; Cohort 2 : At pre-defined interval from Day -5 up to Day 169; Cohort 3: At predefined intervals from Day -5 up to Day 225; Cohort 4: At predefined intervals from Day -5 up to Day 253

  4. Time to reach maximum drug concentration in plasma (tmax) of EE and LEVO

    To assess the effect of multiple doses of AZD6234, multiple doses of co-administered AZD9550 and AZD6234, and multiple doses of AZD9550 on the PK of single doses of CoC EE/LEVO.

    Time frame: Cohort 1: At predefined intervals from Day -5 up to Day 99; Cohort 2 : At pre-defined interval from Day -5 up to Day 169; Cohort 3: At predefined intervals from Day -5 up to Day 225; Cohort 4: At predefined intervals from Day -5 up to Day 253

  5. Elimination half-life (t1/2λz) of EE and LEVO

    To assess the effect of multiple doses of AZD6234, multiple doses of co-administered AZD9550 and AZD6234, and multiple doses of AZD9550 on the PK of single doses of CoC EE/LEVO.

    Time frame: Cohort 1: At predefined intervals from Day -5 up to Day 99; Cohort 2 : At pre-defined interval from Day -5 up to Day 169; Cohort 3: At predefined intervals from Day -5 up to Day 225; Cohort 4: At predefined intervals from Day -5 up to Day 253

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    To assess the safety and tolerability of AZD6234, co-administered AZD9550 and AZD6234, and AZD9550 with CoC EE/LEVO.

    Time frame: Cohort 1: Up to Day 120; Cohort 2: Up to Day 216; Cohort 3: Up to Day 272; Cohort 4: Up to Day 300

  2. Number of participants developing detectable anti-drug antibodies (ADAs) against AZD6234 and AZD9550

    To assess the immunogenicity of AZD6234, co-administered AZD9550 and AZD6234, and AZD9550 with CoC EE/LEVO.

    Time frame: Cohort 1: At predefined intervals from Day -2 up to Day 120; Cohort 2: At predefined intervals from Day -2 up to Day 216; Cohort 3: At predefined intervals from Day -2 up to Day 272; ; Cohort 4: At predefined intervals from Day -2 up to Day 300

  3. Area under plasma concentration-time curve from time 0 to 168 hours postdose (AUC0-168h) of AZD6234

    To characterize the PK of single and multiple doses of AZD6234.

    Time frame: Cohort 1: At predefined intervals from Day 1 to Day 120

  4. AUClast of AZD6234

    To characterize the PK of single and multiple doses of AZD6234.

    Time frame: Cohort 1: At predefined intervals from Day 1 to Day 120

  5. Cmax of AZD6234

    To characterize the PK of single and multiple doses of AZD6234.

    Time frame: Cohort 1: At predefined intervals from Day 1 to Day 120

  6. AUC0-168h of co-administered AZD6234 and AZD9550

    To characterize the PK of single and multiple doses of co-administered AZD6234 and AZD9550.

    Time frame: Cohort 2: At predefined intervals from Day 8 to Day 216; Cohort 4: At predefined intervals from Day 78 to Day 300

  7. AUClast of co-administered AZD6234 and AZD9550

    To characterize the PK of single and multiple doses of co-administered AZD6234 and AZD9550.

    Time frame: Cohort 2: At predefined intervals from Day 8 to Day 216; Cohort 4: At predefined intervals from Day 78 to Day 300

  8. Cmax of co-administered AZD6234 and AZD9550

    To characterize the PK of single and multiple doses of co-administered AZD6234 and AZD9550.

    Time frame: Cohort 2: At predefined intervals from Day 8 to Day 216; Cohort 4: At predefined intervals from Day 78 to Day 300

  9. AUC0-168h of AZD9550

    To characterize the PK of single and multiple doses of AZD9550.

    Time frame: Cohort 3: At predefined intervals from Day 8 up to Day 272

  10. AUClast of AZD9550

    To characterize the PK of single and multiple doses of AZD9550.

    Time frame: Cohort 3: At predefined intervals from Day 8 up to Day 272

  11. Cmax of AZD9550

    To characterize the PK of single and multiple doses of AZD9550.

    Time frame: Cohort 3: At predefined intervals from Day 8 up to Day 272

07

Study locations

2 sites
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    Brooklyn, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2027, 25 months after the start.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 25 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jun 10, 2025
StartActual
Jun 4, 2025
Primary completionEst.
Jul 9, 2027
CompletionEst.
Jul 9, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 13, 2026
Enrollment
50 (estimated)→100 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Active, not recruiting
    Enrollment 50 (estimated)→100 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07013643
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 10, 2025
Start date
Jun 4, 2025
Primary completion
Jul 9, 2027 (estimated)
Completion
Jul 9, 2027 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD6234 · AZD9550

Start the discussion